“Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)”, J of Skin, vol. 1, no. 3.1, p. s24, Oct. 2017, doi: 10.25251/skin.1.supp.23.